About: Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus
Creator	Blouch, Robert Iversen, Patrick Stein, David Huang, Y.-H Kinney, Richard Amantana, Adams Crumley, Stacy Silengo, Shawn
Source	Medline; PMC
abstract	OBJECTIVES: To determine the antiviral activity of phosphorodiamidate morpholino oligomers (PMO) and peptide-conjugated PMO (PPMO) in AG129 mice infected with dengue 2 virus (DENV-2). METHODS: Antisense PMO and PPMO were designed against the 5′ terminal region (5′SL) or the 3′-cyclization sequence region (3′CS) of DENV genomic RNA and administered to AG129 mice before and/or after infection with DENV-2. In addition, cell culture evaluations designed to determine optimum PPMO length, and pharmacokinetic and toxicity analysis of PPMO were also carried out. RESULTS: Mock-treated AG129 mice lived for 9–17 days following intraperitoneal (ip) infection with 10(4)–10(6)pfu of DENV-2 (strain New Guinea C). Intraperitoneal administration of 5′SL or 3′CS PPMO before and after DENV infection produced an increase in the average survival time of up to 8 days. Animals receiving only post-infection PPMO treatment did not benefit significantly. Cell culture studies showed that PPMO of 22–24 bases long produced substantially higher DENV titre reductions than did PPMO that were either shorter or longer. Pharmacokinetic and toxicology analysis with non-infected animals showed that nine consecutive once‐daily ip treatments of 10 mg/kg PPMO resulted in high concentrations of PPMO in the liver and caused little impact on overall health. CONCLUSIONS: The data indicate that PPMO had considerable antiviral efficacy against DENV-2 in the AG129 mouse model and that PPMO treatment early in the course of an infection was critical to extending the survival times of DENV-2-infected mice in the AG129 model system.
has issue date	2008-06-19(xsd:dateTime)
bibo:doi	10.1093/jac/dkn221
bibo:pmid	18567576
has license	no-cc
sha1sum (hex)	9a87ae49de8d7bd0added2594ed04b21a39aec7f
schema:url	https://doi.org/10.1093/jac/dkn221
resource representing a document's title	Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus
has PubMed Central identifier	PMC7109848
has PubMed identifier	18567576
schema:publication	J Antimicrob Chemother
resource representing a document's body	covid:9a87ae49de8d7bd0added2594ed04b21a39aec7f#body_text
is schema:about of	named entity 'VIRUS' named entity 'FOLLOWING' named entity 'DETERMINE' named entity 'ANTIVIRAL ACTIVITY' named entity 'CONJUGATED' named entity 'PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS' named entity 'oligomers' named entity 'CHALLENGE' named entity 'SURVIVAL TIME' covid:arg/9a87ae49de8d7bd0added2594ed04b21a39aec7f named entity 'OLIGOMERS' named entity 'MICE' named entity 'TREATMENT' named entity 'MICE' named entity 'DENGUE' named entity 'ANTISENSE' named entity 'MORPHOLINO' named entity 'INFECTED' named entity 'INCREASES' named entity 'VIRUS' named entity 'PEPTIDE' named entity 'DENGUE' named entity 'OBJECTIVES' named entity 'virus' named entity 'mice' named entity 'DENV' named entity 'phosphorodiamidate morpholino oligomers' named entity 'dengue' named entity 'phosphorodiamidate' named entity 'Balb/c' named entity 'virion' named entity 'PBS' named entity 'arginine' named entity 'peptide' named entity 'melting point' named entity 'infection' named entity 'liver' named entity 'liver' named entity 'DENV' named entity 'PMO' named entity 'PMO' named entity '0.01' named entity 'CPP' named entity 'DENV' named entity 'Drug Administration' named entity 'total bilirubin' named entity 'murine models' named entity 'infection' named entity 'GenBank' named entity 'plasma' named entity 'PBS' named entity 'RBC' named entity 'Institutional Animal Care and Use Committee' named entity 'murine coronavirus' named entity 'viraemia' named entity 'infection' named entity 'St Louis' named entity 'DENV' named entity 'cell-penetrating peptides' named entity 'AVI BioPharma' named entity 'toxicity' named entity 'WHO' named entity 'DHF' named entity 'RBC' named entity 'RNA synthesis' named entity 'DENV' named entity 'Pharmacokinetic' named entity 'flow cytometry' named entity 'toxicity' named entity 'inoculum' named entity 'liver' named entity 'therapeutic applications' named entity 'pathogenesis' named entity 'DENV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software